Frank Richard G
Department of Health Care Policy, Harvard Medical School, Boston, USA.
Health Aff (Millwood). 2003 May-Jun;22(3):46-8. doi: 10.1377/hlthaff.22.3.46.
Two papers in this volume review efforts worldwide to control the growth of drug spending and discuss the potential role for the U.S. government with respect to rationing of prescription drugs. I put the roles given to government in the two papers in context by focusing on the role of government as a partner with the pharmaceutical industry. I concentrate on the unique features of the prescription drug market, coupled with the fact that government is a payer, regulator, and provider in the health sector. I conclude that the federal government should exercise caution when attempting to regulate prescription drug prices.
本卷中的两篇论文回顾了全球控制药品支出增长的努力，并讨论了美国政府在处方药配给方面的潜在作用。我通过关注政府作为制药行业合作伙伴的角色，将两篇论文中赋予政府的角色置于背景之中。我着重探讨了处方药市场的独特特征，以及政府在卫生部门既是支付方、监管方又是供应方这一事实。我的结论是，联邦政府在试图监管处方药价格时应谨慎行事。
